Brian Castillo

Brian Castillo

Auto-generated profile, based on publicly available information

Brian Castillo

Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in The American Journal of Pathology
Verified
Journal Article
Open access
ESEric Salazar
Eric Salazar
PCPaul A. Christensen
Paul A. Christensen
EGEdward A. Graviss
Edward A. Graviss
DNDuc Nguyen
Duc Nguyen
BCBrian Castillo
Brian Castillo
JMJames M. Musser
James M. Musser
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and proven treatments are limited. Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 is among many approaches being studied as potentially efficacious therapy. We are conducting a prospective, propensity score–matched study assessing the efficacy of COVID-19 convalescent plasma transfusion versus standard of care as treatment for severe and/or critical COVID-19. We present herein the results of an interim analysis of 316 patients enrolled at Houston Methodist hospitals from March 28 to July 6, 2020. Of the 316 transfused patients, 136 met a 28-day outcome and were matched to 251 non-transfused control COVID-19 patients. Matching criteria included age, sex, body mass index, comorbidities, and baseline ventilation requirement 48 hours from admission, and in a second matching analysis, ventilation status at day 0. Variability in the timing of transfusion relative to admission and titer of antibodies of plasma transfused allowed for analysis in specific matched cohorts. The analysis showed a significant reduction (P = 0.047) in mortality within 28 days, specifically in patients transfused within 72 hours of admission with plasma with an anti-spike protein receptor binding domain titer of ≥1:1350. These data suggest that treatment of COVID-19 with high anti–receptor binding domain IgG titer convalescent plasma is efficacious in early-disease patients.

1 January 2021 in The American Journal of Pathology
Verified
Journal Article
Closed access
ESEric Salazar
Eric Salazar
PCPaul A. Christensen
Paul A. Christensen
EGEdward A. Graviss
Edward A. Graviss
DNDuc Nguyen
Duc Nguyen
BCBrian Castillo
Brian Castillo
JMJames M. Musser
James M. Musser